Table 5. Associations of pre-treatment patient and tumour characteristics with outcome measures.
| Characteristic | N | % pCR ypT0/is | P-value | % pCR ypT0/is ypN0 | P-value | % pCR ypT0 ypN0 | P-value | RFS hazard ratio (95% CI) | P-value |
|---|---|---|---|---|---|---|---|---|---|
| T-stage |
|
|
0.196 |
|
0.681 |
|
0.591 |
|
0.447 |
| cT1/cT2 | 169 | 8.9 | 2.4 | 1.2 | 1.0 | ||||
| cT3/cT4 |
77 |
3.9 |
|
3.9 |
|
2.6 |
|
0.7 (0.3–1.8) |
|
| N-stage |
|
|
1.0 |
|
0.629 |
|
1.0 |
|
0.315 |
| cN negative | 49 | 6.1 | 4.1 | 2.0 | 1.0 | ||||
| cN positive |
197 |
7.6 |
|
2.5 |
|
1.5 |
|
1.9 (0.6–6.3) |
|
| Histology |
|
|
0.704 |
|
1.0 |
|
0.383 |
|
0.906 |
| Lobular | 33 | 3.0 | 3.0 | 3.0 | 0.9 (0.3–3.1) | ||||
| Ductal |
190 |
7.4 |
|
2.6 |
|
1.1 |
|
1.0 |
|
| Age (years) |
|
|
0.044 |
|
0.044 |
|
0.151 |
|
0.004 |
| <50 | 147 | 10.2 | 4.8 | 2.7 | 1.0 | ||||
| ⩾50 |
99 |
3.0 |
|
0.0 |
|
0.0 |
|
3.5 (1.5–8.3) |
|
| Endocrine responsiveness |
|
|
0.317 |
|
1.0 |
|
1.0 |
|
0.686 |
| Incomplete | 109 | 9.2 | 2.8 | 0.9 | 1.2 (0.5–2.6) | ||||
| (ER or PR <50%) | |||||||||
| High | 129 | 5.4 | 2.3 | 1.6 | 1.0 | ||||
| (ER and PR ⩾50%) |
|
|
|
|
|
|
|
|
|
| SIS (Ki-67) |
|
|
0.056 |
|
0.329 |
|
0.239 |
|
0.049 |
| Luminal A (<14) | 128 | 3.9 | 1.6 | 0.8 | 1.0 | ||||
| Luminal B (⩾14) |
60 |
11.7 |
|
5.0 |
|
3.3 |
|
2.8 (1.0–8.1) |
|
| SIS (grade) |
|
|
0.038 |
|
0.115 |
|
0.203 |
|
0.992 |
| Luminal A (1/2) | 109 | 4.6 | 2.8 | 1.8 | 1.0 | ||||
| Luminal B (3) | 30 | 16.7 | 10.0 | 6.7 | 1.0 (0.3–3.7) |
Abbreviations: CI=confidence interval; pCR=pathologic complete remission; RFS=relapse-free survival; SIS, surrogate intrinsic subtype; ypT0/is=no residual invasive tumour in the breast; ypT0/is ypN0=no residual invasive tumour in breast and lymph nodes; ypT0 ypN0=the absence of any tumour (invasive or non-invasive) in breast and lymph nodes.